Literature DB >> 2680812

Inborn errors of metabolism causing homocysteinemia and related vascular involvement.

F Skovby1.   

Abstract

Sulfur amino acids have been implicated in the pathogenesis of thromboembolic vascular disease, and observations of patients with several inborn errors of metabolism have led to the 'homocysteine theory of arteriosclerosis'. Homocysteine is an intermediate in the transsulfuration pathway and it enters into several other reactions, some of which involve transfer of methyl groups. An abnormally high concentration of homocysteine in the blood causes homocystinuria. Deficiency of cystathionine beta-synthase is the most frequent cause of homocystinuria. Patients with this disorder are at risk for early vascular occlusions. Treatment with vitamin B6 of patients who are biochemically responsive to this vitamin reduces the risk of thromboembolism. Clinical or pathologic evidence of early vascular disease has also been provided in patients with homocysteinemia due to deficient (re)methylation of homocysteine to methionine. This may be caused by a deficiency of 5,10-methylenetetrahydrofolate reductase or by a deficient synthesis of cobalamins.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2680812     DOI: 10.1159/000216088

Source DB:  PubMed          Journal:  Haemostasis        ISSN: 0301-0147


  3 in total

1.  Preventive health care, 2000 update: screening and management of hyperhomocysteinemia for the prevention of coronary artery disease events. The Canadian Task Force on Preventive Health Care.

Authors:  G L Booth; E E Wang
Journal:  CMAJ       Date:  2000-07-11       Impact factor: 8.262

2.  Hyperhomocysteinaemia and premature coronary artery disease in the Chinese.

Authors:  Y I Lolin; J E Sanderson; S K Cheng; C F Chan; C P Pang; K S Woo; J R Masarei
Journal:  Heart       Date:  1996-08       Impact factor: 5.994

3.  Cystathionine beta synthase modulates senescence of human endothelial cells.

Authors:  Eva Albertini; Rafal Kozieł; Angela Dürr; Michael Neuhaus; Pidder Jansen-Dürr
Journal:  Aging (Albany NY)       Date:  2012-10       Impact factor: 5.682

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.